EMEA-000753-PIP01-11
Key facts
Active substance |
Recombinant porcine factor VIII, B-domain deleted
|
Therapeutic area |
Haematology-Hemostaseology
|
Decision number |
P/0040/2012
|
PIP number |
EMEA-000753-PIP01-11
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of acquired haemophilia A
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Baxalta Innovations GmbH
E-mail: medinfoEMEA@takeda.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|